Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors

Proffered Paper Session

November 08, 2012 | Length: 17:52 min

The copyright for all illustrations and pictures has been heeded by all authors to the best of their knowledge. If you feel your copyright has been infringed in any way or if you have any questions, do contact us by clicking on this link, please.

Further Lectures

Using Functional Genetics to Optimize the Treatment of Cancer

Drug Resistance in Targeted Agents

Innate and adaptive immunity regulated within the tumor microenvironment

Microenvironment

Targeting Tumour-Stroma Interaction for Prevention of Metastasis

Microenvironment

Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)

Proffered Paper Session

Go to congress

• Infos